ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

… Plus Enterome And Big Pharma Firms

by Michael McCoy
January 18, 2016 | APPEARED IN VOLUME 94, ISSUE 3

The French biotech firm Enterome has signed deals with two big pharma companies to develop drugs derived from the gut microbiome. Enterome will work with Johnson & Johnson’s Janssen Biotech unit to discover targets and bioactive molecules related to Crohn’s disease. With Takeda Pharmaceutical it will research and develop drugs directed at microbiome targets involved with gastrointestinal disorders. In both deals Enterome is eligible for up-front payments plus research funding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment